DRIVE
Desmopressin for procedures or Radiological InterVEntions
The DRIVE study is now complete.
Chief investigator: Dr Mike Desborough
Primary sponsor: NHSBT
Funder: NHSBT Trust Fund Grant
Summary
A placebo-controlled double-blind, randomised feasibility trial to evaluate the feasibility of administering desmopressin (DDAVP) to Intensive Care patients prior to procedures or radiological interventions, for prophylaxis against bleeding.
Study hypothesis
Approximately one third of patients in intensive care have a low platelet count and the majority undergo at least one invasive procedure during their time in there, putting them at an increased risk of bleeding.
This trial will assess the feasibility of administering desmopressin to thrombocytopenic patients in intensive care prior to a procedure or radiological intervention, for prophylaxis against bleeding.
This trial will also compare haemostatic/platelet function changes before and after administration of the IMP, between the two randomisation groups (desmopressin and placebo). This trial will help to inform the design of a larger randomised controlled efficacy trial of desmopressin vs placebo in intensive care.
Study design
This is a feasibility study and will be run as an interventional, randomised, double-blind, placebo-controlled trial. Patients will be randomised 1:1 using sealed opaque envelopes.
The study will be run and conducted within a single Trust in the UK (Oxford University Hospitals NHS Foundation Trust).